Latest market price
50.69
+1.69+3.45%
Earnings
Up 3.4% — Earnings due 2026-11-04 — pre-report positioning.
Medium confidence
TA
Loading chart...
Snapshot
| Index | — | P/E | 35.00 | EPS (ttm) | 1.40 | Insider Own | 2.75% | Shs Outstand | 80.39M | Perf Week | 1.66% |
| Market Cap | 3.94B | Forward P/E | 25.21 | EPS next Y | 1.94 | Insider Trans | -12.16% | Shs Float | 79.89M | Perf Month | 6.96% |
| Enterprise Value | 3.49B | PEG | 6.18 | EPS next Q | 0.41 | Short Float | 12.29% | Perf Quarter | 5.58% | ||
| Income | 114.00M | P/S | 7.01 | EPS this Y | 14.81% | Short Ratio | 7.24 | Perf Half Y | 46.49% | ||
| Sales | 562.00M | P/B | 2.84 | EPS next Y | 1.80% | ROA | 7.70% | Short Interest | 9.82M | Perf YTD | 16.39% |
| Book/sh | 17.27 | P/C | 8.12 | EPS next 5Y | 5.66% | ROE | 8.64% | 52W High | 60.91 -16.78% | Perf Year | 38.69% |
| Cash/sh | 6.03 | P/FCF | 23.87 | EPS past 3/5Y | — | ROIC | 6.70% | 52W Low | 29.46 72.06% | Perf 3Y | 139.96% |
| Dividend Est. | — | EV/EBITDA | 27.04 | Sales past 3/5Y | 20.29% 34.60% | Gross Margin | 72.09% | Volatility | 5.50% 5.16% | Perf 5Y | 6.73% |
| Dividend TTM | — | EV/Sales | 6.21 | EPS Y/Y TTM | 330.11% | Oper. Margin | 17.03% | ATR (14) | 2.39 | Perf 10Y | 503.45% |
| Dividend Ex-Date | — | Quick Ratio | 8.80 | Sales Y/Y TTM | 17.33% | Profit Margin | 20.37% | RSI (14) | 57.39 | Recom | 2.36 |
| Dividend Gr. 3/5Y | — | Current Ratio | 9.16 | EPS Q/Q | 22.73% | SMA20 | 6.11% | Beta | 1.95 | Target Price | 57.43 |
| Payout | 0.00% | Debt/Eq | 0.02 | Sales Q/Q | 15.38% | SMA50 | 9.98% | Rel Volume | 0.89 | Prev Close | 49.00 |
| Employees | 755 | LT Debt/Eq | 0.02 | Earnings | Nov 04 | SMA200 | 14.32% | Avg Volume | 1.29M | Price | 50.69 |
| IPO Date | Oct 29, 2013 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 31.62% 3.96% | Net Debt/EBITDA | -3.50 | Volume | 1,150,177 | Change | 3.45% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-09-26 | Reiterated | UBS | Buy | $52 → $65 |
| Aug-04-26 | Reiterated | Stephens & Co. | Overweight | $55 |
| Aug-04-26 | Reiterated | Morgan Stanley | Underweight | $47 → $44 |
| Aug-04-26 | Reiterated | Piper Sandler | Overweight | $66 → $54 |
| Aug-03-26 | Reiterated | Canaccord Genuity | Hold | $60 → $50 |
| Jul-31-26 | Reiterated | Needham | Buy | $57 → $69 |
| Jul-30-26 | Reiterated | Needham | Buy | $57 → $69 |
| Jul-15-26 | Reiterated | Piper Sandler | Overweight | $66 |
| Jul-14-26 | Reiterated | Canaccord Genuity | Hold | $42 → $60 |
| Jul-09-26 | Reiterated | Morgan Stanley | Underweight | $37 → $47 |
Latest News· Times ET
Nov-02-26
Nov-02-2609:00AM
Oct-30-26
Oct-29-26
Oct-28-26
Oct-28-2611:06AM
Oct-27-26
Oct-23-26
Oct-23-2604:00AM
Oct-21-26
Oct-20-26
Oct-20-2603:41AM
Oct-19-26
Oct-19-2608:00AM
Oct-16-26
Oct-16-2609:15AM
Oct-14-26
Oct-14-2604:05PM
Oct-13-26
Oct-07-26
Oct-01-26
Sep-29-26
Sep-29-2608:00AM
Company
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 562 | 517 | 446 | 361 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 157 | 157 | 148 | 113 | — | — | — | — | — | |
| Gross Profit | 406 | 360 | 298 | 248 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 202 | 211 | 206 | 184 | — | — | — | — | — | |
| Research and Development | 93 | 71 | 69 | 57 | — | — | — | — | — | |
| Other Operating Expense | 15 | 4 | 7 | 93 | — | — | — | — | — | |
| Operating Income | 96 | 74 | 16 | -86 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 13 | -6 | 10 | 9 | — | — | — | — | — | |
| Net Income Before Taxes | 109 | 68 | 26 | -77 | — | — | — | — | — | |
| Income Taxes | -6 | 2 | 2 | -2 | — | — | — | — | — | |
| Consolidated Net Income | 114 | 66 | 24 | -74 | — | — | — | — | — | |
| Net Income From Continuing Operations | 114 | 66 | 24 | -74 | — | — | — | — | — | |
| Net Income | 114 | 66 | 24 | -74 | — | — | — | — | — | |
| EPS (Recurring) | 1.44 | 0.84 | 0.32 | -1.02 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.44 | 0.84 | 0.32 | -1.02 | — | — | — | — | — | |
| EPS (Diluted) | 1.40 | 0.82 | 0.31 | -1.02 | — | — | — | — | — | |
| EBITDA | 129 | 90 | 49 | -49 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 36.21 | 51.34 | 127.74 | — | — | — | — | — | — | |
| Price To Sales Ratio | 7.22 | 6.43 | 6.75 | 5.56 | — | — | — | — | — | |
| Gross Margin | 72.24 | 69.63 | 66.82 | 68.70 | — | — | — | — | — | |
| Operating Margin | 17.08 | 14.31 | 3.59 | -23.82 | — | — | — | — | — | |
| Net Margin | 20.28 | 12.77 | 5.38 | -20.50 | — | — | — | — | — | |
| Shares Outstanding | 80 | 79 | 76 | 73 | — | — | — | — | — | |
| Market Capitalization | 4,055 | 3,326 | 3,010 | 2,008 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| EASTHAM KARIN | Director | Oct 27 '26 | Option Exercise | 27.01 | 10,000 | 270,100 | 25,097 | Oct 28 |
| Holstein Jens | Director | Oct 27 '26 | Option Exercise | 35.30 | 7,500 | 264,750 | 34,971 | Oct 28 |
| Holstein Jens | Director | Oct 27 '26 | Sale | 50.00 | 7,500 | 375,000 | 27,471 | Oct 28 |
| EASTHAM KARIN | Director | Oct 27 '26 | Sale | 50.00 | 14,850 | 742,573 | 10,247 | Oct 28 |
| Holstein Jens | Director | Sep 24 '26 | Option Exercise | 35.30 | 7,500 | 264,750 | 27,500 | Oct 28 |
| Holstein Jens | Director | Sep 24 '26 | Sale | 47.00 | 7,500 | 352,500 | 27,471 | Oct 28 |
| Bhanji Muna | Director | Oct 19 '26 | Sale | 43.70 | 1,864 | 81,457 | 40,854 | Oct 20 |
| Leite John | Global Chief Commercial Off | Sep 21 '26 | Sale | 40.00 | 4,015 | 160,600 | 124,329 | Sep 22 |
| Holstein Jens | Director | Sep 14 '26 | Sale | 40.95 | 5,000 | 204,747 | 27,471 | Sep 16 |
| Chambers Rebecca | Chief Financial Officer | Sep 04 '26 | Sale | 43.10 | 3,652 | 157,394 | 166,025 | Sep 04 |
| McGuire Annie | EVP, General Counsel | Sep 04 '26 | Sale | 43.09 | 3,254 | 140,212 | 131,160 | Sep 04 |
| Febbo Phillip G. | Chief Scientific & Med Officer | Sep 04 '26 | Sale | 43.05 | 13,110 | 564,410 | 133,048 | Sep 04 |
| Bhanji Muna | Director | Sep 01 '26 | Sale | 42.97 | 1,864 | 80,096 | 42,718 | Sep 03 |
| EASTHAM KARIN | Director | Jun 18 '26 | Sale | 52.89 | 3,729 | 197,234 | 15,097 | Jun 22 |
| McGuire Annie | EVP, General Counsel | Jun 04 '26 | Sale | 49.76 | 3,176 | 158,036 | 137,240 | Jun 04 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.